Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Fabrice André(Institut Gustave Roussy), Ruth O’Regan(Emory University), Mustafa Özgüroğlu(Istanbul University), Masakazu Toi(Kyoto University), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Norikazu Masuda(Osaka National Hospital), Sharon Wilks, Francis P. Arena, Claudine Isaacs(Georgetown University Medical Center), Yoon Sim Yap(National Cancer Centre Singapore), Zsuzsanna Pápai, István Láng(National Institute of Criminology), Anne Armstrong(The Christie NHS Foundation Trust), Guillermo Lerzo(Argentine Naval Hydrographic Service), Michelle White(Moorabbin Hospital), Kunwei Shen(Shanghai Jiao Tong University), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), David Chen(Center for Global Development), Yufen Zhang(Center for Global Development), Shyanne Ali(Center for Global Development), Tetiana Taran(Center for Global Development), Luca Gianni(IRCCS Ospedale San Raffaele)
The Lancet Oncology
April 14, 2014
10.1016/s1470-2045(14)70138-x
Cited by 491

Abstract

Related Papers

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer, John Forster, Deborah Lindquist et al.|New England Journal of Medicine|2006|3.5k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou et al.|Cancer Cell|2004|1.9k
A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
Katrien Berns, Hugo M. Horlings, Bryan T. Hennessy et al.|Cancer Cell|2007|1.6k
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al.|Journal of Clinical Oncology|2010|960
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot, C. Bourgier, Claire Cropet et al.|Journal of Clinical Oncology|2012|709